Clareo Health | A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
52 weeks
Age
12–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study
Adolescents ≥ 12 and \< 18 years of age at the time of the initiation of Dupixent® treatment
You may not be if
\- Adult participants ≥ 18 years of age
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
